Axio BioPharma names Ansa Biotechnologies preferred gene synthesis provider

Axio BioPharma has selected Ansa Biotechnologies as its preferred gene synthesis partner to support Axio Forge, the company’s high-throughput non-GMP antibody lab in Madison, Wisconsin. The move is aimed at reducing early schedule risk in antibody production and improving delivery predictability for research-grade monoclonal antibodies.

Why it matters: - Gene synthesis is the first step in antibody production, so delays there can slow expression, purification, characterization and final delivery. - Axio BioPharma said the partnership with Ansa Biotechnologies is meant to reduce early workflow risk and make customer timelines more predictable. - The deal supports faster biologics development by strengthening an upstream step that often creates schedule uncertainty.

What happened: - Axio BioPharma named Ansa Biotechnologies its preferred gene synthesis provider on August 24, 2026. - Axio Forge already routes gene synthesis to Ansa across its production workflows. - Axio Forge is a high-throughput non-GMP monoclonal antibody laboratory that delivers purified antibodies on a 3-5 week turnaround from electronic sequence. - Axio BioPharma is headquartered in Madison, Wisconsin.

The details: - Ansa’s synthesis platform is built to handle long, complex and scalable DNA constructs. - Ansa’s On-Time Guarantee says complete orders ship by the committed date or the order is free of charge. - Ansa manufactures exclusively in the United States. - Ansa says its products fit into existing workflows and its biosecurity framework meets the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. - Axio Lattice is the company’s coordination and translation layer for pharma sponsors and manufacturing partners to share process data across organizational boundaries without moving data or changing ownership. - Axio Forge produces research-grade monoclonal antibodies on a fee-for-service model.

Between the lines: - The partnership reflects Axio BioPharma’s push to build an ecosystem of specialized technology partners that reduces variability across biologics development. - Axio and Ansa are targeting a common pain point in antibody discovery: upstream delays that can ripple through the rest of the program. - Ansa’s CEO said the collaboration is intended to help researchers move from sequence to purified material with more speed and predictability.

What's next: - Axio BioPharma and Ansa Biotechnologies are positioned to support more antibody programs as demand for faster biologics development rises. - The companies plan to use the combined workflow to provide researchers with a more reliable foundation for antibody discovery. - Axio BioPharma directs readers to learn more at more information.